Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn

Pharmaceutical Business Review

The value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments.

pharminent June 2, 2026 (Last updated: June 4, 2026)

Pharmaceutical Business Review

The value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments.

Related Stories